View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsWellbiotec 過去の業績過去 基準チェック /06Wellbiotecは3.3%の年平均成長率で業績を伸ばしているが、Luxury業界はdecliningで2.7%毎年増加している。売上は減少しており、年平均5.2%の割合である。主要情報3.35%収益成長率20.53%EPS成長率Luxury 業界の成長21.63%収益成長率-5.19%株主資本利益率-85.47%ネット・マージン-16.42%前回の決算情報30 Sep 2025最近の業績更新Reported Earnings • Apr 10Full year 2023 earnings released: ₩820 loss per share (vs ₩325 loss in FY 2022)Full year 2023 results: ₩820 loss per share (further deteriorated from ₩325 loss in FY 2022). Revenue: ₩72.1b (down 54% from FY 2022). Net loss: ₩64.9b (loss widened 211% from FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2023 earnings released: ₩8.00 loss per share (vs ₩63.00 profit in 1Q 2022)First quarter 2023 results: ₩8.00 loss per share (down from ₩63.00 profit in 1Q 2022). Revenue: ₩26.5b (down 57% from 1Q 2022). Net loss: ₩520.6m (down 114% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2022 earnings released: ₩98.00 loss per share (vs ₩383 loss in FY 2021)Full year 2022 results: ₩98.00 loss per share (improved from ₩383 loss in FY 2021). Revenue: ₩190.9b (up 57% from FY 2021). Net loss: ₩6.28b (loss narrowed 70% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₩63.00 (vs ₩44.00 loss in 1Q 2021)First quarter 2022 results: EPS: ₩63.00 (up from ₩44.00 loss in 1Q 2021). Revenue: ₩62.1b (up 262% from 1Q 2021). Net income: ₩3.68b (up ₩5.76b from 1Q 2021). Profit margin: 5.9% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year.すべての更新を表示Recent updatesBoard Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 18Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 17, yeongdong-daero 106-gil, gangnam-gu, seoul South KoreaReported Earnings • Apr 10Full year 2023 earnings released: ₩820 loss per share (vs ₩325 loss in FY 2022)Full year 2023 results: ₩820 loss per share (further deteriorated from ₩325 loss in FY 2022). Revenue: ₩72.1b (down 54% from FY 2022). Net loss: ₩64.9b (loss widened 211% from FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.New Risk • Apr 05New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩53.2b market cap, or US$39.4m).分析記事 • Mar 22Take Care Before Jumping Onto Wellbiotec Co., Ltd. (KRX:010600) Even Though It's 28% CheaperTo the annoyance of some shareholders, Wellbiotec Co., Ltd. ( KRX:010600 ) shares are down a considerable 28% in the...New Risk • Nov 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩134.6b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩134.6b market cap, or US$99.1m).お知らせ • Jun 14Wellbiotec Co., Ltd. announced that it has received KRW 8.00000001 billion in funding from K-Impact FundOn June 13, 2023, Wellbiotec Co., Ltd. closed the transaction.Reported Earnings • May 18First quarter 2023 earnings released: ₩8.00 loss per share (vs ₩63.00 profit in 1Q 2022)First quarter 2023 results: ₩8.00 loss per share (down from ₩63.00 profit in 1Q 2022). Revenue: ₩26.5b (down 57% from 1Q 2022). Net loss: ₩520.6m (down 114% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2022 earnings released: ₩98.00 loss per share (vs ₩383 loss in FY 2021)Full year 2022 results: ₩98.00 loss per share (improved from ₩383 loss in FY 2021). Revenue: ₩190.9b (up 57% from FY 2021). Net loss: ₩6.28b (loss narrowed 70% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Feb 08Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank, Investment ArmWellbiotec Co., Ltd. announced a private placement of series 32 Unsecured privately placed convertible bonds with bearer interest for the gross proceeds of KRW 10,000,000,000 on February 7, 2023. The transaction will include participation from retuning investor Sangsangin Savings Bank, Investment Arm and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 5,000,000,000 each. The bonds are 100% convertible into 8,841,732 shares at a fixed conversion price of KRW 1,131 per share from February 9, 2024 to January 09, 2026. The bonds bear 3% interest rate and 8% yield to maturity and will mature on February 9, 2026. The transaction has been approved by the board of directors and is expected to close on February 9, 2023. The bonds are restricted to a hold period of one year from the date of issuance.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jun 22Wellbiotec Co., Ltd. announced that it expects to receive KRW 3 billion in funding from KH Feelux Co., Ltd.Wellbiotec Co., Ltd. announced a private placement of 31st series no-guaranteed Private convertible bonds with barer type interest part convertible bonds for gross proceeds of KRW 3,000,000,000 on June 21, 2022. The transaction included participation from new investor KH Feelux Co., Ltd. The bonds are having coupon rate 5% and will mature on June 22, 2025. The bonds will be 100% convertible into 1,951,854 common shares of the company at a fixed conversion price of KRW 1,537 per share from June 22, 2023 to May 25, 2025. The board of directors of the company approved the transaction. The subscription and payment date are June 22, 2022.Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₩63.00 (vs ₩44.00 loss in 1Q 2021)First quarter 2022 results: EPS: ₩63.00 (up from ₩44.00 loss in 1Q 2021). Revenue: ₩62.1b (up 262% from 1Q 2021). Net income: ₩3.68b (up ₩5.76b from 1Q 2021). Profit margin: 5.9% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 16Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Wise Pacific Holdings LimitedWellbiotec Co., Ltd. (KOSE:A010600) announced a private placement of round 29th and 30th non-guaranteed private equity convertible bonds with bearer interest for gross proceeds of KRW 10,000,000,000 on April 14, 2021. The transaction will include participation from Rover Holdings Co., Ltd. and returning investor Wise Pacific Holdings Limited for KRW 5,000,000,000 each. The bond is issued at maturity interest rate of 4% and surface interest rate of 0%. The 29th bond will mature on May 14, 2024 and 30th bond will mature on June 14, 2024. The bonds will be 100% convertible into 2,833,662 common shares at a fixed conversion price of KRW 3,529 per share. The 29th bonds will convert from May 14, 2022 to April 14, 2024 and 30th bonds will convert from June 14, 2022 to May 14, 2024. The board of directors of the company approved the transaction. The payment date for 29th bonds is May 14, 2021 and 30th bonds is June 14, 2021.The bonds issued in the transaction will have a hold period of one year from the date of issuance.お知らせ • Mar 11Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021, at 09:00 Korea Standard Time.お知らせ • Feb 27+ 2 more updatesWellbiotec Co., Ltd. announced that it has received KRW 15 billion in funding from Sangsangin Savings Bank, Investment Arm, Sangsangin Plus Savings Bank, Investment ArmOn February 26, 2021, Wellbiotec Co., Ltd. (KOSE:A010600) closed the transaction.Is New 90 Day High Low • Feb 26New 90-day high: ₩2,955The company is up 28% from its price of ₩2,300 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 20% over the same period.Is New 90 Day High Low • Jan 22New 90-day high: ₩2,780The company is up 29% from its price of ₩2,155 on 23 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: ₩2,660The company is up 17% from its price of ₩2,275 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 8.0% over the same period.Is New 90 Day High Low • Dec 15New 90-day high: ₩2,550The company is up 3.0% from its price of ₩2,470 on 16 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 5.0% over the same period.分析記事 • Dec 11Here's Why Wellbiotec (KRX:010600) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Oct 26New 90-day low: ₩2,060The company is down 41% from its price of ₩3,480 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period.Is New 90 Day High Low • Oct 08New 90-day low: ₩2,215The company is down 23% from its price of ₩2,875 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 6.0% over the same period.お知らせ • Aug 27Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion.Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion on August 25, 2020. Wellbiotec Co., Ltd. will acquire 0.05 million shares of Kumyoungeng Co., Ltd. Wellbiotec Co., Ltd. shall pay KRW 2.5 billion as down payment on the contract date, KRW 17.5 billion on October 7, 2020 and balance of KRW 15 billion on November 6, 2020. For the period ending December 2019, Kumyoungeng Co., Ltd reported total assets of KRW 27.75 billion, total equity of KRW 15.86 billion, sales of KRW 50.29 billion and net income of KRW 3.72 billion. The transaction is expected to complete on November 6, 2020.収支内訳Wellbiotec の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSE:A010600 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費30 Sep 2579,765-13,09512,762030 Jun 2582,879-16,60812,806031 Mar 2587,282-17,94712,263031 Dec 2483,301-19,06214,076030 Sep 2446,620-68,65216,661030 Jun 2448,773-65,52519,000031 Mar 2450,873-60,26021,497031 Dec 2359,746-59,08220,956030 Sep 2374,680-22,52518,432030 Jun 2396,222-23,29618,288031 Mar 23122,501-25,08618,808031 Dec 22158,116-20,88119,761030 Sep 22157,959-25,95313,2759730 Jun 22164,626-23,42213,93914731 Mar 22153,331-29,09912,98618631 Dec 21108,377-34,86111,93718630 Sep 21107,138-24,7279,1618930 Jun 2175,149-31,38013,2666431 Mar 2159,256-50,76915,2112831 Dec 2060,431-50,51317,5234230 Sep 2058,699-34,16323,8876130 Jun 2057,809-28,58218,8843931 Mar 2053,086-7,91716,5283631 Dec 1952,333-4,33314,0432230 Sep 1974,363-9,32115,291-1330 Jun 1974,922-11,34513,971-331 Mar 1974,007-11,43612,979-131 Dec 1873,932-13,75412,098030 Sep 1875,574-15,46610,4011630 Jun 1871,854-12,0329,124331 Mar 1872,043-8,0188,322131 Dec 1770,786-8,7427,776030 Sep 1773,822-2,9447,846030 Jun 1779,188-4,7978,037031 Mar 1780,912-4,5028,113031 Dec 1685,292-2,4508,252030 Sep 1693,394-2,1638,188030 Jun 1698,733-1358,217031 Mar 16105,3367668,465031 Dec 15112,4885508,464030 Sep 15115,378-5,5779,334030 Jun 15116,840-5,5799,443031 Mar 15115,684-7,6979,2580質の高い収益: A010600は現在利益が出ていません。利益率の向上: A010600は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A010600は利益を出していないが、過去 5 年間で年間3.3%の割合で損失を削減してきた。成長の加速: A010600の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A010600は利益が出ていないため、過去 1 年間の収益成長をLuxury業界 ( 19.3% ) と比較することは困難です。株主資本利益率高いROE: A010600は現在利益が出ていないため、自己資本利益率 ( -85.47% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YConsumer-durables 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/01/27 03:12終値2026/01/23 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Wellbiotec Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 10Full year 2023 earnings released: ₩820 loss per share (vs ₩325 loss in FY 2022)Full year 2023 results: ₩820 loss per share (further deteriorated from ₩325 loss in FY 2022). Revenue: ₩72.1b (down 54% from FY 2022). Net loss: ₩64.9b (loss widened 211% from FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2023 earnings released: ₩8.00 loss per share (vs ₩63.00 profit in 1Q 2022)First quarter 2023 results: ₩8.00 loss per share (down from ₩63.00 profit in 1Q 2022). Revenue: ₩26.5b (down 57% from 1Q 2022). Net loss: ₩520.6m (down 114% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2022 earnings released: ₩98.00 loss per share (vs ₩383 loss in FY 2021)Full year 2022 results: ₩98.00 loss per share (improved from ₩383 loss in FY 2021). Revenue: ₩190.9b (up 57% from FY 2021). Net loss: ₩6.28b (loss narrowed 70% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₩63.00 (vs ₩44.00 loss in 1Q 2021)First quarter 2022 results: EPS: ₩63.00 (up from ₩44.00 loss in 1Q 2021). Revenue: ₩62.1b (up 262% from 1Q 2021). Net income: ₩3.68b (up ₩5.76b from 1Q 2021). Profit margin: 5.9% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year.
Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 18Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 17, yeongdong-daero 106-gil, gangnam-gu, seoul South Korea
Reported Earnings • Apr 10Full year 2023 earnings released: ₩820 loss per share (vs ₩325 loss in FY 2022)Full year 2023 results: ₩820 loss per share (further deteriorated from ₩325 loss in FY 2022). Revenue: ₩72.1b (down 54% from FY 2022). Net loss: ₩64.9b (loss widened 211% from FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
New Risk • Apr 05New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩53.2b market cap, or US$39.4m).
分析記事 • Mar 22Take Care Before Jumping Onto Wellbiotec Co., Ltd. (KRX:010600) Even Though It's 28% CheaperTo the annoyance of some shareholders, Wellbiotec Co., Ltd. ( KRX:010600 ) shares are down a considerable 28% in the...
New Risk • Nov 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩134.6b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩134.6b market cap, or US$99.1m).
お知らせ • Jun 14Wellbiotec Co., Ltd. announced that it has received KRW 8.00000001 billion in funding from K-Impact FundOn June 13, 2023, Wellbiotec Co., Ltd. closed the transaction.
Reported Earnings • May 18First quarter 2023 earnings released: ₩8.00 loss per share (vs ₩63.00 profit in 1Q 2022)First quarter 2023 results: ₩8.00 loss per share (down from ₩63.00 profit in 1Q 2022). Revenue: ₩26.5b (down 57% from 1Q 2022). Net loss: ₩520.6m (down 114% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2022 earnings released: ₩98.00 loss per share (vs ₩383 loss in FY 2021)Full year 2022 results: ₩98.00 loss per share (improved from ₩383 loss in FY 2021). Revenue: ₩190.9b (up 57% from FY 2021). Net loss: ₩6.28b (loss narrowed 70% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Feb 08Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank, Investment ArmWellbiotec Co., Ltd. announced a private placement of series 32 Unsecured privately placed convertible bonds with bearer interest for the gross proceeds of KRW 10,000,000,000 on February 7, 2023. The transaction will include participation from retuning investor Sangsangin Savings Bank, Investment Arm and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 5,000,000,000 each. The bonds are 100% convertible into 8,841,732 shares at a fixed conversion price of KRW 1,131 per share from February 9, 2024 to January 09, 2026. The bonds bear 3% interest rate and 8% yield to maturity and will mature on February 9, 2026. The transaction has been approved by the board of directors and is expected to close on February 9, 2023. The bonds are restricted to a hold period of one year from the date of issuance.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jun 22Wellbiotec Co., Ltd. announced that it expects to receive KRW 3 billion in funding from KH Feelux Co., Ltd.Wellbiotec Co., Ltd. announced a private placement of 31st series no-guaranteed Private convertible bonds with barer type interest part convertible bonds for gross proceeds of KRW 3,000,000,000 on June 21, 2022. The transaction included participation from new investor KH Feelux Co., Ltd. The bonds are having coupon rate 5% and will mature on June 22, 2025. The bonds will be 100% convertible into 1,951,854 common shares of the company at a fixed conversion price of KRW 1,537 per share from June 22, 2023 to May 25, 2025. The board of directors of the company approved the transaction. The subscription and payment date are June 22, 2022.
Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₩63.00 (vs ₩44.00 loss in 1Q 2021)First quarter 2022 results: EPS: ₩63.00 (up from ₩44.00 loss in 1Q 2021). Revenue: ₩62.1b (up 262% from 1Q 2021). Net income: ₩3.68b (up ₩5.76b from 1Q 2021). Profit margin: 5.9% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 16Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Wise Pacific Holdings LimitedWellbiotec Co., Ltd. (KOSE:A010600) announced a private placement of round 29th and 30th non-guaranteed private equity convertible bonds with bearer interest for gross proceeds of KRW 10,000,000,000 on April 14, 2021. The transaction will include participation from Rover Holdings Co., Ltd. and returning investor Wise Pacific Holdings Limited for KRW 5,000,000,000 each. The bond is issued at maturity interest rate of 4% and surface interest rate of 0%. The 29th bond will mature on May 14, 2024 and 30th bond will mature on June 14, 2024. The bonds will be 100% convertible into 2,833,662 common shares at a fixed conversion price of KRW 3,529 per share. The 29th bonds will convert from May 14, 2022 to April 14, 2024 and 30th bonds will convert from June 14, 2022 to May 14, 2024. The board of directors of the company approved the transaction. The payment date for 29th bonds is May 14, 2021 and 30th bonds is June 14, 2021.The bonds issued in the transaction will have a hold period of one year from the date of issuance.
お知らせ • Mar 11Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021, at 09:00 Korea Standard Time.
お知らせ • Feb 27+ 2 more updatesWellbiotec Co., Ltd. announced that it has received KRW 15 billion in funding from Sangsangin Savings Bank, Investment Arm, Sangsangin Plus Savings Bank, Investment ArmOn February 26, 2021, Wellbiotec Co., Ltd. (KOSE:A010600) closed the transaction.
Is New 90 Day High Low • Feb 26New 90-day high: ₩2,955The company is up 28% from its price of ₩2,300 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 20% over the same period.
Is New 90 Day High Low • Jan 22New 90-day high: ₩2,780The company is up 29% from its price of ₩2,155 on 23 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: ₩2,660The company is up 17% from its price of ₩2,275 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Dec 15New 90-day high: ₩2,550The company is up 3.0% from its price of ₩2,470 on 16 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 5.0% over the same period.
分析記事 • Dec 11Here's Why Wellbiotec (KRX:010600) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Oct 26New 90-day low: ₩2,060The company is down 41% from its price of ₩3,480 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period.
Is New 90 Day High Low • Oct 08New 90-day low: ₩2,215The company is down 23% from its price of ₩2,875 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 6.0% over the same period.
お知らせ • Aug 27Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion.Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion on August 25, 2020. Wellbiotec Co., Ltd. will acquire 0.05 million shares of Kumyoungeng Co., Ltd. Wellbiotec Co., Ltd. shall pay KRW 2.5 billion as down payment on the contract date, KRW 17.5 billion on October 7, 2020 and balance of KRW 15 billion on November 6, 2020. For the period ending December 2019, Kumyoungeng Co., Ltd reported total assets of KRW 27.75 billion, total equity of KRW 15.86 billion, sales of KRW 50.29 billion and net income of KRW 3.72 billion. The transaction is expected to complete on November 6, 2020.